Data Year:

For its 2024 fiscal year, ARROWHEAD PHARMACEUTICALS, INC., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Christopher Anzalone
President and Chief Executive Officer
Total Compensation $12,423,473 View details Pay Rank By Title In Biotechnology industry #74 View more
Kenneth Myszkowski
Chief Financial Officer
Total Compensation $3,512,376 View details Pay Rank By Title In Biotechnology industry #120 View more
Patrick O'Brien
Chief Operating Officer and General Counsel
Total Compensation $3,933,570 View details Pay Rank By Title In Biotechnology industry #39 View more
James Hamilton
Chief of Discovery and Translational Medicine
Total Compensation $3,487,444 View details Pay Rank By Title In Biotechnology industry #2 View more
Javier San Martin
Former Chief Medical Officer
Total Compensation $3,456,564 View details Pay Rank By Title In Biotechnology industry #73 View more
Tracie Oliver
Former Chief Commercial Officer
Total Compensation $3,076,780 View details Pay Rank By Title In Biotechnology industry #97 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at ARROWHEAD PHARMACEUTICALS, INC. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. ARROWHEAD PHARMACEUTICALS, INC. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. ARROWHEAD PHARMACEUTICALS, INC. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Christopher Anzalone
President and Chief Executive Officer
Total Cash $2,103,012 Equity $10,319,000 Other $1,461 $12,423,473
Kenneth Myszkowski
Chief Financial Officer
Total Cash $906,865 Equity $2,589,750 Other $15,761 $3,512,376
Patrick O'Brien
Chief Operating Officer and General Counsel
Total Cash $983,259 Equity $2,935,050 Other $15,261 $3,933,570
James Hamilton
Chief of Discovery and Translational Medicine
Total Cash $882,433 Equity $2,589,750 Other $15,261 $3,487,444
Javier San Martin
Former Chief Medical Officer
Total Cash $260,529 Equity $2,589,750 Other $606,285 $3,456,564
Tracie Oliver
Former Chief Commercial Officer
Total Cash $484,065 Equity $2,589,750 Other $2,965 $3,076,780
For its 2024 fiscal year, ARROWHEAD PHARMACEUTICALS, INC., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Christopher Anzalone CEO Pay $12,423,473 Median Employee Pay $174,364 CEO Pay Ratio 71:1
For its 2024 fiscal year, ARROWHEAD PHARMACEUTICALS, INC., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Adeoye Olukotun Total Cash $460,833
Douglass Given Total Cash $475,833
Hongbo Lu Total Cash $804,999
Mauro Ferrari Total Cash $460,833
Michael S. Perry Total Cash $460,833
Victoria Vakiener Total Cash $460,833
William Waddill Total Cash $470,833
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.